CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
VarmX is developing VMX-C001, a safe reversal agent for Factor Xa Direct Oral Anticoagulants. This innovation addresses a critical need for patients at risk of severe bleeding due to blood-thinning medications.
50 Million patients worldwide use oral anticoagulants to prevent venous thrombosis and stroke.
Since the last decade, unpredictable and risky indirect anticoagulant treatments are being replaced by the latest generation of blood-thinning medication:
Factor Xa Direct Oral Anticoagulants (FXa-DOACs, used by >10 million patients in EU+US).
With superior predictability, efficacy and safety profiles, these life-saving medications remain associated with a risk of uncontrolled and severe bleeding.
Alar…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
